AMIODARONE THERAPY IN PATIENTS WITH HCM AND REFRACTORY CARDIAC SYMPTOMS

一项正在进行的临床试验已经制定，以评估 口服胺碘酮治疗慢性阻塞性肺疾病的疗效观察 肥厚型心肌病和难治性心脏病 心脏病突发的高危症状或患者 死亡。在过去的一年里，我们完成了一项研究 目前包括72名肥厚型心肌病患者(41名 正负14年)作为两项议定书的一部分：第1组-- 顽固性心脏症状患者(n=50)和第二组- 猝死高危患者(n=22)。尽管 第一组患者症状改善，脑室缩小 第1组和第2组患者在随访期间的心律失常 期间(662加或减273天)，8例患者发生心脏骤停 死亡(累积存活率=88%)。突然死亡似乎是 在患者开始应用胺碘酮治疗后早期发生 有严重的心脏症状，后来在高 心脏性猝死的危险变量。不幸的是，我们 结论：胺碘酮不能预防，而且可能会增加 某些亚型心源性猝死患者的临床研究 肥厚型心肌病。

An ongoing clinical trial has been formulated to assess the therapeutic efficacy of oral amiodarone in patients with hypertrophic cardiomyopathy and either refractory cardiac symptoms or patients who are at high risk for sudden cardiac death. Over the past year, we have completed a study which now includes 72 patients with hypertrophic cardiomyopathy (41 plus or minus 14 years) as part of two protocols: Group 1 - patients with refractory cardiac symptoms (n=50) and Group 2 - patients who are at high risk for sudden death (n=22). Despite improved symptoms in Group 1 patients, and reduced ventricular arrhythmias in Group 1 and 2 patients, during the follow-up period (662plus or minus 273 days), 8 patients had sudden cardiac death (cummulative survival=88%). Sudden death appeared to occur early after instituting amiodarone treatment in patients with severe cardiac symptoms, and later in patients with high risk variables for sudden cardiac death. Unfortunately, we conclude that amiodarone does not prevent and may increase sudden cardiac death in certain subsets of patients with hypertrophic cardiomyopathy.